About company
Hillstream BioPharma is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (“IMCD”) for treatment resistant cancers. Their most advanced product candidate is HSB-1216, an IMCD inducer, targeting a variety of solid tumors. In a clinical pilot study conducted in Germany by the University of Heidelberg, the active drug in HSB-1216 was found to reduce tumor burden in treatment resistant cancers, including triple negative breast cancer (“TNBC”) and epithelial carcinomas. Their goal is to submit an investigational new drug application (“IND”) to the U.S. Food and Drug Administration (“FDA”) in 2022 and start a clinical study with HSB-1216 in 2022; however, no assurance can be provided that their IND will be accepted by the FDA in 2022, if at all. If their IND is accepted by the FDA, their HSB-1216 clinical study will focus on expanding upon the clinical pilot study conducted in Germany. If they are able to start their clinical study with HSB-1216 in 2022, they anticipate that initial data from such trial will be released either the end of 2022 or early 2023. They use Quatramer, their proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (“TME”) with an extended duration of action and minimal off-target toxicity.
|
Industry
|
|
Pharmaceutical Preparations
|